Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2003 Mar 4;100(5):2742-7.
doi: 10.1073/pnas.0530192100. Epub 2003 Feb 24.

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

W A Erik Marijt  1 , Mirjam H M Heemskerk, Freke M Kloosterboer, Els Goulmy, Michel G D Kester, Menno A W G van der Hoorn, Simone A P van Luxemburg-Heys, Manja Hoogeboom, Tuna Mutis, Jan Wouter Drijfhout, Jon J van Rood, Roel Willemze, J H Frederik Falkenburg
Affiliations
Case Reports

Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia

W A Erik Marijt et al. Proc Natl Acad Sci U S A. .

Abstract

Donor lymphocyte infusion (DLI) into patients with a relapse of their leukemia or multiple myeloma after allogeneic stem cell transplantation (alloSCT) has been shown to be a successful treatment approach. The hematopoiesis-restricted minor histocompatibility antigens (mHAgs) HA-1 or HA-2 expressed on malignant cells of the recipient may serve as target antigens for alloreactive donor T cells. Recently we treated three mHAg HA-1- and/or HA-2-positive patients with a relapse of their disease after alloSCT with DLI from their mHAg HA-1- and/or HA-2-negative donors. Using HLA-A2HA-1 and HA-2 peptide tetrameric complexes we showed the emergence of HA-1- and HA-2-specific CD8(+) T cells in the blood of the recipients 5-7 weeks after DLI. The appearance of these tetramer-positive cells was followed immediately by a complete remission of the disease and restoration of 100% donor chimerism in each of the patients. Furthermore, cloned tetramer-positive T cells isolated during the clinical response specifically recognized HA-1 and HA-2 expressing malignant progenitor cells of the recipient and inhibited the growth of leukemic precursor cells in vitro. Thus, HA-1- and HA-2-specific cytotoxic T lymphocytes emerging in the blood of patients after DLI demonstrate graft-versus-leukemia or myeloma reactivity resulting in a durable remission. This finding implies that in vitro generated HA-1- and HA-2-specific cytotoxic T lymphocytes could be used as adoptive immunotherapy to treat hematological malignancies relapsing after alloSCT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
HA-1 and HA-2 tetramer+ T cells in peripheral blood from patient 1 in relation to clinical effect. (a) CD8+/tetramer+ T cells are expressed as absolute numbers per milliliter in peripheral blood (left y axis). ■, CD8+/HA-2 tetramer+ T cells; ♦, CD8+/HA-1 tetramer+ T cells; *, CD8+/HY-A2 tetramer+ T cells; ○, white blood cell count (WBC) × 106 per ml in peripheral blood (expressed on the right y axis). The black arrow depicts the moment of DLI. (b) BCR/ABL (■) is expressed as the ratio of BCR/ABL/household gene porphobilinogen deaminase mRNA. The lower level of detection is ≤10−5.
Figure 2
Figure 2
HA-1 and HY/B7 tetramer+ T cells in peripheral blood from patient 2 in relation to clinical effect. See the legend to Fig. 1 for a description of symbols and abbreviations used. ▵, CD8+/HY-B7 tetramer+ T cells.
Figure 3
Figure 3
HA-1 tetramer+ T cells in peripheral blood from patient 3 in relation to clinical effect. (a) See the legends to Figs. 1 and 2 for a description of symbols and abbreviations used. (b) ♦, M protein is expressed in grams/liter in peripheral blood. The lower level of detection is <1 g/liter.
Figure 4
Figure 4
Percentage lysis of EBV-LCLs and CML cells from patient 1 by different CTL clones as measured in the 51Cr-release assay. (Left) Lysis of EBV-LCLs. (Right) Lysis of CML cells. Gray bars, 20-h incubation; white bars, 4-h incubation.
Figure 5
Figure 5
Percentage of growth inhibition by different CTL clones in the HPC growth-inhibition assay. Effector cells: (a) high-affinity anti-HA-1 CTL clone; (b) intermediate affinity anti-HA-1 CTL clone; (c and d) high-affinity anti-HA-2 CTL clones; (e) control anti-HLA-A1/HY CTL clone. Target cells: ♦, donor HPCs; ■, recipient CML HPCs before transplantation; ○, recipient CML HPCs at relapse; x, unrelated CML patient X; *, unrelated CML patient Y; +, unrelated CML patient Z. On the x axis the E/T ratio is shown. Tissue typing: CML-X ♀, HLA-A2, HA-1-positive, HA-2-positive; CML-Y ♂, HLA-A1, -A2, HA-1-positive, HA-2-negative; and CML-Z ♂, HLA-A2, HA-1-negative, HA-2-positive.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kolb H J, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Blood. 1990;76:2462–2465. - PubMed
    1. Kolb H J, Schattenberg A, Goldman J M, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Blood. 1995;86:2041–2050. - PubMed
    1. Collins R H, Shpilberg O, Drobyski W R, Porter D L, Giralt S, Champlin R, Goodman S A, Wolff S N, Hu W, Verfaillie C, et al. J Clin Oncol. 1997;15:433–444. - PubMed
    1. Porter D L, Collins R H, Jr, Hardy C, Kernan N A, Drobyski W R, Giralt S, Flowers M E, Casper J, Leahey A, Parker P, et al. Blood. 2000;95:1214–1221. - PubMed
    1. Dazzi F, Szydlo R M, Craddock C, Cross N C, Kaeda J, Chase A, Olavarria E, van Rhee F, Kanfer E, Apperley J F, et al. Blood. 2000;95:67–71. - PubMed

Publication types

MeSH terms